A transcript of the video narration is below:
My name is Leon Herndon, and I’m a professor of ophthalmology at Duke University Eye Center. I’m presenting at the American Glaucoma Society meeting in Washington, DC, and I’m happy to share the results of a poster that was presented this morning.
We wanted to look at how effective are MIGS [minimally invasive glaucoma surgery] procedures among African-American patients. African-American patients typically, as you may know, have more advanced glaucoma and some surgeons may not know MIGS play a role for African-American patients. We were able to look at IRIS registry data, over 18,000 eyes, most of whom had just cataract surgery by themselves. We also looked at 3 different subsets of MIGS patients: Hydrus Microstent (Alcon), iStent inject (Glaukos), and Omni (Sight Sciences) patients. We looked at patients out to 36 months to see how those MIGS patients do compared to the cataract surgery group alone. At 36 months we showed that MIGS were very effective. Particularly Omni at 36 months required fewer medications than the other two MIGS groups. If you follow just cataract patients alone, especially those who presented with lower pressures, we found that the pressures elevated over time to 36 months.
I think that the take-home point is that MIGS is effective, even among African-American patients. We show an opportunity [to address] an unmet need here, because 17,000 of these eyes had just cataract surgery alone. These are glaucoma patients, so those are missed opportunities to decrease medications among these patients. [Another] take-home point is to consider MIGS procedures among all patients, including African-American patients, who are having cataract surgery. GP
